San Diego-based Cypress Bioscience and its partner, New York-based Forest Laboratories, said today they got positive results from a final-stage study of 1,025 patients with fibromyalgia. The patients took either milnacipran or a placebo, and a greater proportion of patients on the drug experienced at least a 30 percent reduction in pain from when they entered the study and rated themselves “very much improved” or much improved. The companies have applied for FDA clearance to market this drug based on two previous Phase III trials that reached their goals, but the application has been delayed.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
